This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yang, Y. Articles by Hellström, K. E. Search for Related Content PubMed PubMed Citation Articles by Yang, Y. Articles by Hellström, K. E.

Tumor Cells Expressing Anti-CD137 scFv Induce a Tumor-Destructive Environment

Department of Pathology, University of Washington, Seattle, Washington

Requests for reprints: Karl Erik Hellström, Department of Pathology, University of Washington, Box 35 99 39, Harborview Medical Center, 325 Ninth Avenue, Seattle, WA 98109-2499. Phone: 206-341-4714; E-mail: hells{at}u.washington.edu.

For immunotherapy to become more effective, there is a need to maximize the antitumor response at the tumor site as well as to eliminate tumor cell variants that lack a given tumor antigen or the ability to present it. We have previously shown that wild-type (WT) cells from the K1735 melanoma (K1735-WT) are rejected following vaccination with cells (K1735-1D8) transfected to express scFv from the anti-CD137 monoclonal antibody 1D8, and that CD4⁺ T cells and natural killer (NK) cells are needed for this rejection. We now show that tumors harvested 4 to 10 days after mice had been transplanted with K1735-1D8 cells or a mixture of K1735-1D8 and K1735-WT cells contained more NK cells and that they had an increased percentage of CD4⁺ T lymphocytes producing IFN or tumor necrosis factor-. We further show that the percentage of NK cells was higher in B16-1D8 melanomas expressing anti-CD137 scFv than in the WT tumors and that the percentage of FoxP3⁺ cells was lower. Admixture of 10% K1735-1D8 cells prevented the progressive growth of transplanted K1735-WT cells in syngeneic mice and also of cells from the antigenically different sarcoma Ag104. Inhibition of WT tumor cells by tumor cells transfected to express anti-CD137 scFv was shown also with the TC1 carcinoma and B16 melanoma. Furthermore, injection of an adenovirus vector, Ad-1D8, which encodes anti-CD137 scFv into established B16 melanomas, significantly prolonged the survival of tumor-bearing mice and could induce regression. Our data suggest that targeting of anti-CD137 scFv to tumors should be explored for therapy for some human cancers. [Cancer Res 2007;67(5):2339–44]

This article has been cited by other articles:

				M. Gil, M. Bieniasz, A. Wierzbicki, B. J. Bambach, H. Rokita, and D. Kozbor Targeting a Mimotope Vaccine to Activating Fc{gamma} Receptors Empowers Dendritic Cells to Prime Specific CD8+ T Cell Responses in Tumor-Bearing Mice J. Immunol., November 15, 2009; 183(10): 6808 - 6818. [Abstract] [Full Text] [PDF]

				C.-H. Lee, Y.-H. Chiang, S.-E. Chang, C.-L. Chong, B.-M. Cheng, and S. R. Roffler Tumor-Localized Ligation of CD3 and CD28 with Systemic Regulatory T-Cell Depletion Induces Potent Innate and Adaptive Antitumor Responses Clin. Cancer Res., April 15, 2009; 15(8): 2756 - 2766. [Abstract] [Full Text] [PDF]

				B. K. Choi, Y. H. Kim, W. J. Kang, S. K. Lee, K. H. Kim, S. M. Shin, W. M. Yokoyama, T. Y. Kim, and B. S. Kwon Mechanisms Involved in Synergistic Anticancer Immunity of Anti-4-1BB and Anti-CD4 Therapy Cancer Res., September 15, 2007; 67(18): 8891 - 8899. [Abstract] [Full Text] [PDF]